T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
BACKGROUND
Adoptive cell therapy with engineered T cells expressing chimeric antigen receptors (CARs) originated from antibodies is a promising strategy in cancer immunotherapy. Several unsuccessful trials, however, highlight the need for alternative conventional binding domains and the better combination of costimulatory endodomains for CAR construction to improve the effector functions of the engineered T cells. Camelid single-domain antibodies (VHHs), which are the smallest single domain antibodies, can endow great targeting ability to CAR-engineered T cells.


METHODS
We have developed a method to generate genetically engineered Jurkat T cells armed with a CAR comprising the anti-HER2 VHH as targeting moiety. From an immune camel library, five VHH clones were selected as a set of oligoclonal anti-HER2 VHHs that exhibited diverse binding abilities and joined them to CD28-CD3ζ and CD28-OX40-CD3ζ signaling endodomains. Jurkat T cells expression of VHH-CARs and cell functions were evaluated.


RESULTS
The oligoclonal engineered T cells showed higher proliferation, cytokine secretion and cytotoxicity than each individual VHH-CAR-engineered Jurkat T cells.


CONCLUSIONS
The combination of superior targeting ability of oligoclonal VHHs with the third generation CAR can substantially improve the function of engineered T cells.


CONCLUSIONS
Antigen-specific directed oligoclonal T cells are alternatively promising, but safer systems, to combat tumor cells.
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Fatemeh Rahimi
FR
Jamnani
Fatemeh
F
Rahbarizadeh
Mohammad Ali
MA
Shokrgozar
Fereidoun
F
Mahboudi
Davoud
D
Ahmadvand
Zahra
Z
Sharifzadeh
Ladan
L
Parhamifar
S Moein
SM
Moghimi
D017209:Apoptosis; D015153:Blotting, Western; D049109:Cell Proliferation; D064987:Cell- and Tissue-Based Therapy; D005434:Flow Cytometry; D006801:Humans; D019169:Jurkat Cells; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D015202:Protein Engineering; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D011946:Receptors, Antigen / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D061905:Single-Domain Antibodies / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D014407:Tumor Cells, Cultured
D018719:Erb-b2 Receptor Tyrosine Kinases; D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins; D061905:Single-Domain Antibodies
3,3′,5,5′-tetramethyl benzidine; CAR; CDR; Chimeric antigen receptor; HCAb; HER2; IPTG; MHC; Oligoclonal T cell therapy; Single domain antibodies (VHH); T cell receptor; TAG 72; TCR; TMB; VHH; VHH-CAR; VHH-chimeric antigen receptor; chimeric antigen receptor; complementarity determining region; heavy-chain antibodies; isopropyl-β-D-thio-galactoside; major histocompatibility complex; tumor associated glycoprotein 72; variable domain of camel heavy-chain antibody